Tenofovir Nephrotoxicity: 2011 Update
Author Information
Author(s): Beatriz Fernandez-Fernandez, Ana Montoya-Ferrer, Ana B. Sanz, Maria D. Sanchez-Niño, Maria C. Izquierdo, Jonay Poveda, Valeria Sainz-Prestel, Natalia Ortiz-Martin, Alejandro Parra-Rodriguez, Rafael Selgas, Marta Ruiz-Ortega, Jesus Egido, Alberto Ortiz
Primary Institution: IIS-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
Hypothesis
What are the risks and mechanisms of nephrotoxicity associated with tenofovir use in HIV treatment?
Conclusion
Tenofovir can cause nephrotoxicity characterized by proximal tubular cell injury, which may lead to conditions like Fanconi syndrome and acute kidney injury.
Supporting Evidence
- Tenofovir is associated with a small but significant risk of acute kidney injury.
- Proximal tubular dysfunction may occur even with normal glomerular filtration rates.
- Withdrawal of tenofovir often leads to improvement in renal function.
- Monitoring renal function in high-risk patients is crucial to minimize nephrotoxicity.
- New tenofovir derivatives are being studied to reduce nephrotoxic effects.
Takeaway
Tenofovir, a medicine for HIV, can hurt your kidneys, but stopping the medicine usually helps the kidneys get better.
Methodology
The review summarizes evidence from clinical trials, case reports, and observational studies regarding tenofovir's nephrotoxic effects.
Potential Biases
Clinical trials often have strict criteria that may not reflect real-world patient conditions, potentially underestimating nephrotoxicity.
Limitations
The review may not account for all patient demographics and conditions that could influence nephrotoxicity outcomes.
Participant Demographics
The study includes HIV-infected individuals, with varying degrees of renal function and comorbidities.
Statistical Information
P-Value
0.7%
Confidence Interval
95% CI 2.1–5.7 mL/min
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website